Combination therapies with EHMT2 inhibitors
US11672800B2 · kind B2 · utility
3Cited by
21References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2018 |
| Grant date | Jun 13, 2023 |
| Priority date | — |
| Expiry date | Feb 13, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.